Al­bireo caps a big week with back-to-back ap­provals in the US/EU for the first drug to treat a se­vere liv­er dis­ease

Al­bireo $AL­BO CEO Ron Coop­er is get­ting his long-await­ed shot at mar­ket­ing the first drug ap­proved for pru­ri­tus in all sub­types of pro­gres­sive fa­mil­ial in­tra­hep­at­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER